According to Coherent Market Insights, the global chronic kidney disease drugs market is estimated to be valued at US$ 12,328.2 million in 2020 and is expected to exhibit a CAGR of 4.0% during the forecast period (2020-2027).
Key Trends and Analysis of the Global Chronic Kidney Disease Drugs Market:
Key trends in the market include rising prevalence of chronic kidney disease, product approvals & launches for the treatment of chronic kidney disease, and adoption of inorganic growth strategies by market players. For instance, according to the Quality and Outcomes Framework (QOF) and the UK Renal Registry data, the prevalence of chronic kidney disease (stage 3-5) in England was around 4.09 per 100 in people of age 18 years and above in 2018.
Key players operating in the market are focusing on novel product launches and approvals, in order to expand their product portfolio and strengthen their presence in the global market. For instance, in September 2019, Kissei Pharmaceutical Co., Ltd. and JCR Pharmaceuticals Co., Ltd. collaboratively developed and received marketing approval in Japan for Darbepoetin Alfa BS Injection, a biosimilar of darbepoetin alfa, indicated for the treatment of renal anemia in patients with chronic kidney disease (CKD).
Moreover, in November 2018, November, Kissei Pharmaceutical Co., Ltd. launched P-TOL Granules (250 mg and 500 mg) tablets indicated for the treatment of hypophosphatemia in patients with chronic kidney disease on dialysis.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1713
Furthermore, majority of the pharmaceutical manufacturers operating in the chronic kidney disease drugs market are engaged in the adoption of inorganic growth strategies such as collaborations, partnerships, and acquisitions to strengthen their market share, which is fuelling growth of the global chronic kidney disease drugs market.
Key Market Takeaways:
The global chronic kidney disease drugs market is expected to exhibit a CAGR of 4.0% during the forecast period, owing to increasing prevalence of chronic kidney disease across the globe. For instance, according to Lancet data in 2017, prevalence of chronic kidney disease in Southeast Asia was found to be 69,598,036 and total 134,459 deaths were seen due to chronic kidney disease in the same region.
Among drug type, Erythropoiesis-stimulating Agents(ESAs) segment is estimated to hold a dominant position in the global chronic kidney disease drugs market in 2020, owing to recent regulatory approvals of novel products of this drug type by key players in the global market.
Among regions, North America is estimated to hold largest market share in the global chronic kidney disease drugs market in 2020, owing to increase in awareness campaigns for chronic kidney disease, higher prevalence of chronic kidney disease and favorable reimbursement policies in the region.
Key players operating in the global chronic kidney disease drugs market include Amgen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, Hoffmann La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., Reata Pharmaceuticals, Inc., GlaxoSmithKline Plc, and Ardelyx, Inc.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1713
Global Chronic Kidney Disease Drugs Market, By Drug Type:
Calcium Channel Blockers
Erythropoiesis-stimulating Agents (ESAs)
Global Chronic kidney Disease Drugs Market, By Route of Administration:
Global Chronic kidney Disease Drugs Market, By Patient Type:
Global Chronic Kidney Disease Drugs Market, By Distribution Channel:
Global Chronic Kidney Disease Drugs Market, By Region:
Rest of Latin America
Rest of Europe
Rest of Asia Pacific
Rest of Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201125005473/en/
Senior Client Partner – Business Development
Coherent Market Insights
Follow Us: LinkedIn | Twitter